Recruiting
Phase 3

VK2735

Sponsor:

Viking Therapeutics, Inc.

Code:

NCT07868835

Conditions

Weight Loss

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VK2735

Placebo comparator

Study Details

Brief summary:

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.

Conditions

Weight Loss

Study ID

NCT07868835

Start date

Nov, 2026

Status verified date

Nov, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Jul, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age ≥18 years of age at the time of signing the informed consent.
2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).

  • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
  • Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure.
  • BMI calculated at the screening visit will be used to determine eligibility.

Exclusion Criteria:

1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (excluding liposuction or abdominoplasty if performed >1 year prior to screening)
4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy
6. Treatment with glucose-lowering agent(s) within 90 days before screening
7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
8. History of acute or chronic pancreatitis

Study Design

Enrollment

560 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Placebo Assignment

Placebo comparator orally once daily

experimental: Active Assignment (Dose 1)

VK2735 Dose level 1 orally once daily

experimental: Active Assignment (Dose 2)

VK2735 Dose level 2 orally once daily

experimental: Active Assignment (Dose 3)

VK2735 Dose level 3 orally once daily

Interventions

VK2735

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Placebo comparator

Placebo comparator administered orally once daily

Primary outcome measure

  • Percentage change in body weight for participants receiving VK2735 orally once daily [ Time Frame: 68 weeks ]

Central Contacts and Locations

Locations

Viking Clinical Site #1020

Recruiting

Tucson, Arizona, United States, 85741

Contacts

Viking Clinical Site #1018

Recruiting

Chula Vista, California, United States, 91910

Contacts

Viking Clinical Site #1015

Recruiting

Lake Forest, California, United States, 92630

Contacts

Viking Clinical Site #1005

Recruiting

Melbourne, Florida, United States, 32934

Contacts

Viking Clinical Site #1003

Recruiting

The Villages, Florida, United States, 32162

Contacts

Viking Clinical Site #1013

Recruiting

Atlanta, Georgia, United States, 30329

Contacts

Viking Clinical Site #1001

Recruiting

Evansville, Indiana, United States, 47714

Contacts

Viking Clinical Site #1009

Recruiting

Valparaiso, Indiana, United States, 46383

Contacts

Viking Clinical Site #1014

Recruiting

Louisville, Kentucky, United States, 40213

Contacts

Viking Clinical Site #1004

Recruiting

Richfield, Minnesota, United States, 55423

Contacts

Viking Clinical Site #1029

Recruiting

Jackson, Mississippi, United States, 39206

Contacts

Viking Clinical Site #1028

Recruiting

Springfield, Missouri, United States, 65807

Contacts

Viking Clinical Site #1006

Recruiting

Rochester, New York, United States, 14609

Contacts

Viking Clinical Site #1035

Recruiting

Morehead City, North Carolina, United States, 28557

Contacts

Viking Clinical Site #1023

Recruiting

Medford, Oregon, United States, 97504

Contacts

Viking Clinical Site #1002

Recruiting

East Greenwich, Rhode Island, United States, 02818

Contacts

Viking Clinical Site #1030

Recruiting

Henderson, Tennessee, United States, 37075

Contacts

Viking Clinical Site #1031

Recruiting

Abilene, Texas, United States, 79606

Contacts

Viking Clinical Site #1026

Recruiting

Salt Lake City, Utah, United States, 84124

Contacts

Viking Clinical Site #1011

Recruiting

Seattle, Washington, United States, 98105

Contacts

More Information

Sponsor

Viking Therapeutics, Inc.

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • Body Weight Changes
  • Body Weight
  • Weight Loss

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Viking Therapeutics, Inc. on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.